CCNU是一种被人们认为对恶性胶质瘤敏感的化疗药物,本文作者认为以往对恶性胶质瘤治疗效果的报告在控制研究条件方面不够严格,因此,作者选择从1970年11月至1972年12月期间,在某医院经过统一手术、病理诊断的63例幕上3～4级胶质瘤病人,分成三组进行治疗,观察其疗效。这三组是:一、CCNU化疗组;二、放射治疗组;三、联合治疗组。这些病例大部分作了肿瘤次全切除,7例作了近于全切除,8例仅作活检。作者在二组应用CCNU治疗的剂量是:130毫克/平方米,只要是病人来院求治则间隔8周给药一次,除非发现有持续的骨髓抑制时才减少用量。对接受放射治疗的两组病人,均给予超高压装置(CO~(60)或4～6百万电子伏线形电子加速器)作全脑照射治疗。中线组织吸收剂量为5000拉德(rads)。治疗结果:截至1975年4月止,63例病人仅2例存活。各组疗效如下:单纯放射治疗组22例,1 CCNU is a kind of chemotherapeutic drug thought to be sensitive to malignant gliomas. The authors believe that the previous reports on the therapeutic effects of malignant gliomas are not strict enough to control the study conditions. Therefore, the author chose to go from November 1970 to 1972. During the month of December, 63 cases of patients with on-screen grade 3 to 4 gliomas undergoing unified surgery and pathological diagnosis in a hospital were divided into three groups for treatment and their efficacy was observed. The three groups were: CCNU chemotherapy group; radiotherapy group; and combination therapy group. In most of these cases, subtotal tumor resection was performed, in 7 cases nearly complete resection was performed, and in 8 cases only biopsy was performed. The dose of CCNU in the two groups was 130 mg/m2, and was administered once every 8 weeks as long as the patient came to the hospital. The dose was reduced only if persistent myelosuppression was found. For both groups of patients undergoing radiation therapy, ultra-high pressure devices (CO~(60) or 4~6 million electron-volt-shaped electron accelerators) were used for whole brain irradiation. The midline tissue absorbed a dose of 5000 rads. Treatment outcome: As of April 1975, only 2 of 63 patients survived. The efficacy of each group was as follows: 22 patients with radiotherapy alone, 1